Publication
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (7)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 7
- cancerMelanomacivic_curation1.00
- drugDabrafenibcivic_curation1.00
- drugTrametinibcivic_curation1.00
- geneBRAFcivic_curation1.00
- variantBRAF V600civic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantBRAF V600Kcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25265492
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V6001 | ||||||||
| Dabrafenib + TrametinibCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 5 | accepted | EID6937In this Phase III trial (NCT01584648 COMBI-d), 423 previously untreated patients with unresectable stage IIIC or IV BRAF V600E or V600K mutant melanoma received dabrafenib and trametinib or dabrafenib… (full text at CIViC) PMID 25265492 · Long et al., 2014 · Open in CIViC | civic |
| BRAF V600E1 | ||||||||
| Dabrafenib + TrametinibCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 5 | accepted | EID6938In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unresectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and t… (full text at CIViC) PMID 25265492 · Long et al., 2014 · Open in CIViC | civic |
| BRAF V600K1 | ||||||||
| Dabrafenib + TrametinibCombination | Melanoma | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID6939In this Phase III trial (NCT01584648 COMBI-d), previously untreated patients with unrescectable stage IIIC or IV melanoma with BRAF V600E (359 patients) or V600K (61 patients) received dabrafenib and … (full text at CIViC) PMID 25265492 · Long et al., 2014 · Open in CIViC | civic |